Skip Navigation


NDT Advance Access originally published online on September 27, 2006
Nephrology Dialysis Transplantation 2007 22(1):25-27; doi:10.1093/ndt/gfl557
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/1/25    most recent
gfl557v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Beimler, J.
Right arrow Articles by Zeier, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beimler, J.
Right arrow Articles by Zeier, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

ABO-incompatible transplantation—a safe way to perform renal transplantation?

Jörg Beimler and Martin Zeier

Department of Nephrology, University of Heidelberg, Heidelberg, Germany

Correspondence and offprint requests to: Jörg Beimler, Nierenzentrum Heidelberg, Department of Nephrology, University of Heidelberg, Im Neuenheimer Feld 162, 69120 Heidelberg, Germany. Email: beimler@gmx.de

Keywords: ABO-incompatible renal transplantation; desensitization; immunoadsorption; living kidney donation; plasmapheresis; rituximab

The first 150 words of the full text of this article appear below.

The shortage of donor organs, especially in renal transplantation, leads to an increasing discrepancy between the number of end-stage renal disease patients on waiting lists and the number of available deceased donor kidneys. Expansion of the donor pool can be achieved by increasing the numbers of living kidney transplantation and by overcoming the immunological barriers of ABO-incompatibility and HLA-sensitization. Despite a substantial increase in the number of patients, receiving living kidney transplant, otherwise suitable donors have to be rejected due to pre-existing human leuocyte antigen antibodies or ABO-incompatibility. Isoagglutinins (ABO-antibodies) represent a major barrier in optimizing living kidney donation and organ distribution. As blood group antigens are expressed by the endothelium of solid organs including the kidney, transplantation across the blood group barrier can result in hyperacute antibody-mediated allograft rejection. Depending on blood group distributions in different populations, as much as 30–35% of potential living donors have to be excluded . . . [Full Text of this Article]



   The European way
 


   The Japanese way
 


   The American way
 


   ABO-incompatible renal transplantation—questions to be answered
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?